Co nowego w terapii cukrzycy typu 1

• Authors: Noczyńska Anna , Zubkiewicz-Kucharska Agnieszka , Nocoń-Bohusz Julita
• Languages of publication: PL

Keywords

PL

cukrzyca typu 1; prewencja cukrzycy; nowe metody leczenia; nowe metody monitorowania.

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2012
• Issue: 3
• Pages: 474-481

Contributors

author

Noczyńska Anna

author

Zubkiewicz-Kucharska Agnieszka

author

Nocoń-Bohusz Julita

References

• Pociot F, McDermott M. Genetics of type 1 diabetes mellitus. Genes Immun 2002, 3: 235–49.
• Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.Nat Rev Drug Discov 2011; 10(6): 439−452.
• Akerblom HK, Virtanen SM, Honen J, et al. Dietary manipulation of β-cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 2005; 48: 829−837.
• Hyppönen E, Läärä E, Reunanen A. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358: 1500–1503.
• Walter M, Kaupper T, Adler K, et al. No effect of the 1 alpha, 25-dihydroxyvitamin D3 on β-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diab Care 2010; 33(7): 1443−1448.
• Marjamäki L, Niinistö S, Kenward MG, et al. Maternal intake of vitamin D during pregnancy and risk of advanced β cell autoimmunity and type 1 diabetes in offspring. Diabetologia 2010; 53(8): 1599−1607.
• Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34(4): 408−415.
• Weigmann BD, von Boehmer HB. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med 2011; 208(7):1501–1510.
• Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378(9788): 319−327.
• Ludwigson J, Faresjö M, Hjorth M, et al. GAD treatment and Insulin Secretion in Recent Onset Type 1 Duiabetes. N Engl J Med 2008; 359: 1909−1920.
• Ludvigsson J, Hjorth M, Chéramy M, et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011; 54(3): 634−640.
• Sobel DO, Henzke A, Abbassi V, et al. Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol 2010; 47(3): 243−250.
• Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual β cell mass. Diabetologia 2010; 53(4): 614−623.
• Raz I, Elias D, Avron A, Tamir M, et al. Β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358: 1749––1753.
• Herold KC, Pescovitz MD, McGee P, et al. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 2011; 187(4).
• Sherry N, Hogopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege Study): 1-year results from a randomised, placebo – controlled trial. Lancet 2011; 378(9790): 487−497.
• Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378(9789): 412−419.
• Wegner O, Wyka K, Fendler W, et al. Ocena zachowanej przetrwałej insulinosekrecji u dzieci i młodzieży z cukrzycątypu 1. Pediatr Endocrinol Diab Metabol 2010; 16(2): 67−71.
• Meier JJ, Butler AE, Saisho Y, et al. Β-cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans. Diabetes 2008; 57(6): 1584−1594.
• Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301(15): 1573−1579.
• Volterelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297(14): 1568−1576
• Snarski E, Milczarczyk A, Torosian P, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transpl 2011; 46(4): 562−566.
• Berman A, Pawelec K, Fiedor P. Allogeniczne przeszczepianie izolowanych wysp trzustkowych w praktyce klinicznej.Pol Arch Med Wewn 2009; 119(5): 326−332.
• Steiner S, Hompesch M, Pohl R, et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008; 51(9): 1602−1606.
• Lih A, Hibbert E, Wong T, et al. The role of insulin glulisine to improve glycemic control in children with diabetes mellitus. Diab Metab Syndr Obes 2010; 3: 403−412.
• Hompesch M, McManus L, Pohl R, et al. Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diab Sci Technol 2008; 2(4): 568−571.
• Forst T, Pfützner A, Flacke F et al. Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diab Care 2010; 33(1): 116−120.
• Cobry E, McFann K, Messer L. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diab Technol Ther 2010; 12(3): 173−177.
• Birkeland KI, Home PD, Wendisch U. Insulin degludec in type 1 diabetes: a randomized controlled trial of a newgeneration ultra-long-acting insulin compared with insulin glargine. Diab Care 2011; 34(3): 661−665.
• Zinman B, Fulcher G, Rao PV. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.Lancet 2011; 377(9769): 924−931
• The Hormone Foundation’s Patient Guide to Continuous Glucose Monitoring. http://www.hormone.org/Resources/upload/Continuous-Glucose-Monitoring-Web.pdf.
• Continuous Glucose Monitoring Improves Glycemic Control. http://www.physiciansbriefing.com/Article.asp?AID=659200.
• Cygnus Corp: www.glucowatch.com.
• Garg SG, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with Type 1 Diabetes. Diab Care 2004; 27(3) 734−738.
• Graydon O. Eye sensor simplifies glucose tests. Opto@LaserEurope:opticsorg. articles/news2005:11.
• Chen CS, Wang KK, Jan MY, et al. Nonivasive blood glucose monitoring using the optical signal of pulsatile microcirculation:a pilot study in subjects with diabetes. J Diab /Its Complications 2008; 22: 371−376.
• Herbrechtsmeier P, Mueller AJ, Hasslacher C, et al. New optical method for blood glucose self-monitaring. Diabetologia 2009; 52(Suppl. 1): 369.
• Barone PW, Parker RS, Strano MS. In vivo fluorescence detection of glucose using a single-walled carbon nonotube optical sensor: design fluorophore properties, advantages and disadvantages. Anal Chem 2005; 77: 7556−7562.
• Minh TD, Oliver SR, Engo J, et al. Non-invasive measurement of plasma glucose from exhaled breath in healthy and type 1 diabetic mellitus subject. ADA 2011: Abstract 875–P.
• Kerr D, Hoogma RP, Buhr A, et al. Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion. J Diab Sci Technol 2010; 4(6): 1400−1407.
• Jenkins AJ, Krishnamurthy B, Best JD, et al. Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels: a randomized controlled trial. Diab Care 2010; 33(6): 1242−1248.
• Bondia J, Dassau E, Zipser H, et al. Coordinated Basal-Bolus Infusion for tighter postprandial glucose control in insulin pump therapy. J Diab Sc Technol 2009; 3: 1.
• Zisser H, Wagner R, Pleus S, et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head-to-head comparison. Diab Technol Ther 2010; 12(12): 955−961.
• Grosman B, Dassau E, Zisser HC, et al. Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events. J Diab Sci Technol 2010; 4(4): 961−975.
• Buckingham B, Chase HP, Dassau E, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diab Care 2010; 33(5): 1013−1037.
• Ziegler R, Heidtmann B, Hilgard D, et al. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diab 2011; 12(1): 11−17.
• Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363(4): 311−320. Epub 2010 Jun 224.
• Dassau E, Cameron F, Lee H, et al. Real-Time hypoglycemia prediction suite using continuous glucose monitoring: a safety net for the artificial pancreas. Diab Care J Diab Sci Technol 2010; 4(4): 913−922.